Novel CRISPR Cas13a-gRNA expression vector and application thereof
An expression vector, a new type of technology, applied in the biological field of cancer gene therapy, can solve the problem of knocking down the expression of tumor-promoting genes in cancer cells
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0055] pDCUg knocks down target gene expression in cancer cells in vivo and in vitro and inhibits tumor growth in vivo
[0056] 1. Materials and methods
[0057] 1.1, carrier structure
[0058] The chemically synthesized NF-κB specific promoter (DMP) was cloned into pMD19-T simple (TAKARA) to obtain pMD19-T-DMP. The human codon-optimized Cas13a coding sequence was amplified from pC013-Twinstrep-SUMO-huLwCas13a (Addgene) by PCR, and cloned into pMD19-T-DMP to obtain pMD19-T-DMP-Cas13a. The chemically synthesized U6 promoter sequence and the direct repeat sequence of the guide RNA (gRNA) separated by the BbsI restriction site were cloned into pMD19-T-DMP-Cas13a to generate the pDMP-Cas13a-U6-gRNA vector ( Referred to as pDCUg). Table 1 lists the genes targeted by gRNA and their target sequences.
[0059] Table 1. Target sequence of guide RNA in Cas13a-gRNA interference test
[0060]
[0061]
[0062] Note: PFS is the protospacer flanking site (the flanking site of the original spacer)...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com